Company Overview and News

9
Intellia Therapeutics: Left Behind The Cas9 Excitement

17h seekingalpha
Without a Phase I trial upcoming soon, while their competitors progress in that regard, the company will continue to underperform the CRISPR trio moving forward.
NTLA EDIT BLUE CRSP NVS BLUE

4
Biotech Analysis Central Pharma News: Celgene's Protocol Change, Roche's BLA For Herceptin, Amgen's Resubmission For Osteoporosis

2018-07-16 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
AMGN BLUE HALO CELG BLUE

10
Dopamine and the Weather, Part 2

2018-07-13 zacks
Welcome back to Mind Over Money. I’m Kevin Cook, your field guide and story teller for the fascinating arena of behavioral economics.
ACAD BIIB BLUE CRSP NVDA BLUE SAM

2
BLUE / bluebird bio, Inc. 8-K (Current Report)

2018-07-12 sec.gov
blue-8k_20180712.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BLUE

7
Celgene Reports Positive Data on Tecentriq, Abraxane Study

2018-07-11 zacks
Celgene Corporation (CELG - Free Report) announced positive results from a late-stage study on oncology drug, Abraxane, in combination with Roche’s (RHHBY - Free Report) immuno-oncology drug, Tecentriq.
LMT XLRN CELGZ JUNO BLUE CELG BLUE

7
Celgene, Acceleron Report Positive Data on Thalassemia Drug

2018-07-10 zacks
Celgene Corporation (CELG - Free Report) and partner Acceleron Pharma Inc. (XLRN - Free Report) announced positive results from a second randomized, double-blind, multi-center clinical phase III study, BELIEVE, on pipeline candidate, luspatercept.
XLRN CELGZ UNP JUNO BLUE CELG BLUE

2
Financial Exchange Stock Talk: Joe McCann On Loxo Oncology And bluebird bio

2018-07-10 seekingalpha
We now partner with Financial Exchange Radio to produce a weekly segment with Seeking Alpha authors.
BLUE LOXO BLUE

10
Sangamo: Foundational Platform's Path To Clinical Validation

2018-07-09 seekingalpha
SB-525 for Hemophilia is now Phase II per Pfizer. This represents the initial trial for Sangamo's Gene Therapy Platform. This initial data readout is due in late summer.
NTLA EDIT BLUE CRSP BLUE FIXX PFE

7
Celgene (CELG) Down 21% So Far in 2018: What Lies Ahead?

2018-07-09 zacks
Shares of Celgene Corporation (CELG - Free Report) have been down 21% in the year so far compared to a 3.3% decline for the overall biotech industry.
XLRN CELGZ JUNO BLUE CELG CVRR BLUE

14
Your Daily Pharma Scoop: Review Of 3 More Stocks From The Biotech Boom IPO Week (18 - 22 June)

2018-07-04 seekingalpha
Like we said in our previous article on biopharma IPOs, the IPO scene is suddenly buzzing with a lot of excitement. A staggering eight biotech companies were in the process of going public. There are 31 biotech companies that joined the IPO bandwagon this H1, which is more than the number that did so in entire 2012. Even if suddenly it seems that everything is right about the sector, the sector fans certainly know that such booms are usually followed by sharp corrections.
XERS SHPG EIDX AVRO TOCA JUNO NVO LLY BLUE SNY

32
The Real Test For Gene Therapy Is Yet To Come

2018-06-27 biospace
It feels like we’re standing on the edge of a precipice. Despite the ho-hum recent performance of biotech stocks, amazing things are about to happen. And one of the most amazing of all is gene therapy.
GILD IONS PTCT BLUE ONCE

153
Autolus IPO: 25% In Cash Per Share, And U.K. Government Financing

2018-06-25 seekingalpha
Cash per share represents about 25% of the stock’s value, at the trading price of $25.
SGEN AMGN CELGZ GILD CELG AUTL NVS BLUE GSK CSBTF

108
Genomic Medicine: Is The Platform The FDA Product?

2018-06-25 seekingalpha
Gene therapy platforms are improving at a rapid pace, becoming reliable products leveraged across entire pipelines.
NTLA EDIT BLUE CELG NVS CRSP BLUE FIXX PFE RGNX

35
Sell Kraft-Heinz At $64-65 - Cramer's Lightning Round (6/21/18)

2018-06-22 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, June 21.
STOR WPM REGN FRT BLUE XEC KHC BLUE FCF FRT.PRC

19
Cramer's lightning round: The key level for selling Kraft-Heinz

2018-06-21 cnbc
The Kraft-Heinz Company: "Kraft-Heinz has just moved up very quickly, but I do think with rates going down the stock still has some upside. I want you at $64, $65 to sell it, though, because I still need some growth."
WPM STOR FCF BLUE

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to BLUE / bluebird bio, Inc. on message board site Silicon Investor.

Daily Bluegrass Blue Eyes Crying in the Rain
bluebird bio Inc. Blueprint Medicines
BTV.V - Bluerush Media Group Blue Coat Inc.
Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG Blue Water Global Group Inc.
MIDNIGHT BLUES CAFE Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG (MODERATED)
CUSIP: 09609G100